JP2012532619A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012532619A5 JP2012532619A5 JP2012520015A JP2012520015A JP2012532619A5 JP 2012532619 A5 JP2012532619 A5 JP 2012532619A5 JP 2012520015 A JP2012520015 A JP 2012520015A JP 2012520015 A JP2012520015 A JP 2012520015A JP 2012532619 A5 JP2012532619 A5 JP 2012532619A5
- Authority
- JP
- Japan
- Prior art keywords
- dom1h
- tnfr1
- antagonist
- tnfα
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims 28
- 239000005557 antagonist Substances 0.000 claims 26
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims 24
- 238000003556 assay Methods 0.000 claims 15
- 230000001404 mediated effect Effects 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 108060003951 Immunoglobulin Proteins 0.000 claims 6
- 102000018358 immunoglobulin Human genes 0.000 claims 6
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 4
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102000057041 human TNF Human genes 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000036963 noncompetitive effect Effects 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 101100425753 Homo sapiens TNFRSF1A gene Proteins 0.000 claims 2
- 101100425754 Mus musculus Tnfrsf1a gene Proteins 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000001900 immune effect Effects 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22609409P | 2009-07-16 | 2009-07-16 | |
| US61/226,094 | 2009-07-16 | ||
| PCT/EP2010/060111 WO2011006914A2 (en) | 2009-07-16 | 2010-07-14 | Antagonists, uses & methods for partially inhibiting tnfr1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012532619A JP2012532619A (ja) | 2012-12-20 |
| JP2012532619A5 true JP2012532619A5 (enExample) | 2013-08-29 |
Family
ID=43304850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520015A Pending JP2012532619A (ja) | 2009-07-16 | 2010-07-14 | Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20120107330A1 (enExample) |
| EP (1) | EP2453920A2 (enExample) |
| JP (1) | JP2012532619A (enExample) |
| CA (1) | CA2768460A1 (enExample) |
| WO (1) | WO2011006914A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010215482B2 (en) * | 2009-02-19 | 2014-02-13 | Glaxo Group Limited | Improved anti-serum albumin binding variants |
| BRPI1008014A2 (pt) * | 2009-02-19 | 2016-10-04 | Glaxo Group Ltd | domínio variável simples, ligante multiespecífico, antagonistas de tnfr1, e de receptor de tnf-alfa, uso do agonista de tnfr, antagonista anti-tnfr1, polipeptídeo ou ligante multiespecífico, método para tratar e/ou prevenir uma condição ou doença, ácido nucleico, vetor, e, hospedeiro |
| WO2011008814A2 (en) * | 2009-07-14 | 2011-01-20 | Immune Tolerance Institute, Inc., A California Not-For-Profit Corporation | Multiplexed measurement of exogenous and endogenous dna |
| EA201291009A1 (ru) | 2010-05-20 | 2013-05-30 | Глаксо Груп Лимитед | Улучшенные связывающие варианты против сывороточного альбумина |
| WO2015104322A1 (en) | 2014-01-09 | 2015-07-16 | Glaxosmithkline Intellectual Property Development Limited | Treatment of inflammatory diseases with non-competitive tnfr1 antagonists |
| WO2015187651A1 (en) | 2014-06-02 | 2015-12-10 | Li-Cor, Inc. | Therapeutic and diagnostic probes |
| CN111565731B (zh) | 2017-10-24 | 2024-03-08 | 达莉亚·伊兰妮 | 治疗缺血性疾病的方法 |
| US12472266B2 (en) | 2019-02-21 | 2025-11-18 | Enosi Therapeutics Corporation | Antibodies and enonomers |
| JP2023541816A (ja) | 2020-08-27 | 2023-10-04 | イノージ・セラピューティクス・コーポレイション | 自己免疫性疾患および癌を治療するための方法および組成物 |
| US20220288226A1 (en) * | 2020-08-27 | 2022-09-15 | Enosi Life Sciences Corp. | Methods and compositions to treat autoimmune diseases and cancer |
| WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
| EP4355381A1 (en) * | 2021-06-17 | 2024-04-24 | Immunicom, Inc. | Modified tnf as a capture ligand |
| CN114699533B (zh) * | 2022-05-06 | 2023-05-09 | 郑州大学 | 一种核酸适配体和多肽交联的双靶点复合核酸纳米药物制备方法与应用 |
| WO2024165823A2 (fr) | 2023-02-09 | 2024-08-15 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Fragment fab mutant pour l'obtention de conjugués mono- ou bi-fonctionnalisés site-spécifiques |
| WO2025049818A1 (en) | 2023-08-29 | 2025-03-06 | Enosi Therapeutics Corporation | Tnfr1 antagonists lacking agonist activity and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA94040A (en) | 1904-09-04 | 1905-07-04 | Emile Leo Behrmann | Machine for making boxes or wrappers |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
| EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
| US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| DK1801214T3 (da) | 1997-07-07 | 2011-01-24 | Medical Res Council | In vitro sorteringsfremgangsmåde |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| WO2001058953A2 (en) | 2000-02-11 | 2001-08-16 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function |
| DE60237282D1 (de) | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
| WO2003076567A2 (en) | 2002-03-05 | 2003-09-18 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| US20060002935A1 (en) * | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| EP3299393A1 (en) | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| CA2511910A1 (en) | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| EP2357237A1 (en) | 2003-05-14 | 2011-08-17 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
| DK1639011T3 (da) | 2003-06-30 | 2009-02-16 | Domantis Ltd | Pegylerede enkelt-domæne antistoffer (dAb) |
| SI1729795T1 (sl) | 2004-02-09 | 2016-04-29 | Human Genome Sciences, Inc. | Albuminski fuzijski proteini |
| PT1737962E (pt) | 2004-03-24 | 2010-12-03 | Domantis Ltd | Sequência líder universal gas1 |
| GB0418651D0 (en) | 2004-08-20 | 2004-09-22 | Medical Res Council | Method |
| GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| BRPI0518762A2 (pt) | 2004-12-02 | 2008-12-09 | Domantis Ltd | fusço de droga, conjugado de droga, Ácido nucleico recombinante ou isolado, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir a fusço de droga, composiÇço farmacÊutica, mÉtodo para tratamento de um indivÍduo tendo uma doenÇa inflamatària, uso de um conjugado de droga ou fusço de droga, e, composiÇço de droga |
| FR2903032B1 (fr) | 2006-06-29 | 2008-10-17 | Ecole Polytechnique Etablissem | "procede et dispositif d'usinage d'une cible par faisceau laser femtoseconde." |
| KR20100018040A (ko) * | 2007-06-06 | 2010-02-16 | 도만티스 리미티드 | 프로테아제 내성 폴리펩티드를 선택하는 방법 |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| BRPI1008014A2 (pt) * | 2009-02-19 | 2016-10-04 | Glaxo Group Ltd | domínio variável simples, ligante multiespecífico, antagonistas de tnfr1, e de receptor de tnf-alfa, uso do agonista de tnfr, antagonista anti-tnfr1, polipeptídeo ou ligante multiespecífico, método para tratar e/ou prevenir uma condição ou doença, ácido nucleico, vetor, e, hospedeiro |
-
2010
- 2010-07-14 JP JP2012520015A patent/JP2012532619A/ja active Pending
- 2010-07-14 WO PCT/EP2010/060111 patent/WO2011006914A2/en not_active Ceased
- 2010-07-14 EP EP10737010A patent/EP2453920A2/en not_active Withdrawn
- 2010-07-14 US US13/383,856 patent/US20120107330A1/en not_active Abandoned
- 2010-07-14 CA CA2768460A patent/CA2768460A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012532619A5 (enExample) | ||
| JP2012517818A5 (enExample) | ||
| Wendt et al. | CCR9 antagonism: potential in the treatment of inflammatory bowel disease | |
| JP2019504086A5 (enExample) | ||
| JP2012021001A5 (enExample) | ||
| JP2014503482A5 (enExample) | ||
| JP2012070740A5 (enExample) | ||
| US20200024354A1 (en) | Baff selective binding compounds and related methods | |
| JP2008507536A5 (enExample) | ||
| JP2017029157A5 (enExample) | ||
| JP2016041733A5 (enExample) | ||
| JP2018505158A5 (enExample) | ||
| JP2014169326A5 (enExample) | ||
| JP2010524489A5 (enExample) | ||
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| JP2015522252A5 (enExample) | ||
| JP2019521647A5 (enExample) | ||
| JP2015525230A5 (enExample) | ||
| JP2019510739A5 (enExample) | ||
| JP2012509269A5 (enExample) | ||
| JP2017523776A5 (enExample) | ||
| JP2020510000A5 (enExample) | ||
| JP2014516924A5 (enExample) | ||
| JP2020531030A5 (enExample) | ||
| JP2017530372A5 (enExample) |